Jasper Therapeutics, Inc.
NASDAQJasper Therapeutics enters its May 19 earnings report with two analyst downgrades landing the same morning, a stock trading near the floor of its recent range, and a clinical setback still casting a shadow over the lead program. The analyst community turned sharply more cautious Friday. TD Cowen dropped its rating from Buy to Hold — no longer willing to argue for upside — just…
Snapshot as of 16 May 2026
Jasper Therapeutics enters its May 19 earnings report with two analyst downgrades landing the same morning, a stock trading near the floor of its recent range, and a clinical setback still casting a shadow over the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for JSPR — free to start on ORTEX.
Sign up for free →Open JSPR on ORTEX